Companies · ABT
Abbott Laboratories
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Jul 28, 2026
Abbott closes $20.6B Exact Sciences acquisition; Diagnostic Products soar 22.4%, CGM systems drive 8.6% growth.
Abbott completed its transformative $20.6 billion acquisition of Exact Sciences on March 23, 2026, establishing market leadership in cancer diagnostics and adding $1.0 billion in incremental revenue in the first half of 2026. Total company sales rose 8.2% excluding FX headwinds, with Diagnostic Products surging 22.4% (driven by Exact Sciences' Cologuard, Oncotype DX, and Cancerguard), Medical Devices climbing 8.0% led by 13.0% growth in Electrophysiology and 8.2% expansion in Diabetes Care (particularly CGM systems at $4.1 billion YTD). Acquired debt of $2.8 billion was nearly eliminated by June 30, 2026, and Abbott funded the deal via $20.0 billion in new long-term debt and cash on hand, maintaining its A+/Aa3 investment-grade ratings.
Tone: bullishRevenue
$44.3B
ABT 10-K · FY 2025
Employees
115,000
Revenue FY2024
$42B
Founded
1900
Profile
ABT 10-K Item 1 · Feb 20, 2026Abbott Laboratories is a diversified global healthcare company engaged in the discovery, development, manufacture, and sale of medical devices, diagnostic products, nutritional products, and branded generic pharmaceuticals. The company operates across four reportable segments and sells its products in more than 160 countries. Abbott is pursuing entry into the cancer diagnostics market through a pending acquisition of Exact Sciences Corporation.
Read filing description ↓ Collapse description ↑
Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment markets branded generic pharmaceuticals in emerging markets across broad therapeutic areas including gastroenterology, women's health, cardiovascular and metabolic conditions, pain and central nervous system disorders, respiratory drugs and vaccines, and biologics. The Diagnostic Products segment manufactures and markets core laboratory and transfusion medicine systems, molecular diagnostics PCR systems, point-of-care systems, rapid diagnostics lateral flow testing products, and informatics and automation solutions sold worldwide to blood banks, hospitals, commercial laboratories, clinics, and other care settings. The Nutritional Products segment offers pediatric and adult nutritional products, including infant formula, follow-on formula, and enteral nutrition products, marketed and sold worldwide to consumers, healthcare facilities, and institutional customers. The Medical Devices segment provides rhythm management, electrophysiology, heart failure, vascular, and structural heart devices, as well as continuous glucose monitoring systems, blood glucose monitoring systems, and neuromodulation devices for the management of chronic pain and movement disorders. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market.
Primary products
- Creon
- Duspatal
- Dicetel
- Heptral
- Transmetil
- Samyr
Business segments
End markets
Geographies
“Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Abbott's 2025 sales growth was primarily attributable to the performance of the Medical Devices and Established Pharmaceutical Products segments, partially offset by continued decline in COVID-19 testing-related sales in the Diagnostics segment.
The rest of ABT is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.